why choose us

First received: July 04, 2023

Clinical Trial: Abemaciclib in Newly Diagnosed Meningioma Patients

Study Status: NOT_YET_RECRUITING

Recruit Status: NOT_YET_RECRUITING

Condition: Meningioma

Study Type: INTERVENTIONAL


Official Title: A Phase 2 Multicenter, Double-blind, Randomized-controlled Study of Abemaciclib (CDK4 and 6 Inhibitor) in Newly Diagnosed RB-proficient Grade 3 Meningioma Participants

Brief Summary: This study is being done to learn about how an investigational drug called abemaciclib works in treating patients with a newly-diagnosed grade 3 meningioma.Abemaciclib is a drug that is approved by the FDA, but not for brain tumors.Participants who consent to the trial will have surgical tissue collected from the planned surgical resection and tested.If the tissue shows positive results for RB cells and participants are qualified, they will be enrolled and receive study treatment two to five weeks after completing…

Read more